The global
antibiotic resistance market comprises pharmaceutical therapeutics addressing
the growing issue of antibiotic resistance. Key products include antibiotics,
vaccines, and diagnostic kits that can detect new and emerging drug-resistant
bacterial strains. The rising threat of multidrug-resistant pathogens is
driving massive R&D investments into novel treatment approaches like
monoclonal antibodies, gene therapy, and antipathogenic compounds.
The Global Antibiotic Resistance Market is estimated
to be valued at US$ 8.83 Bn in 2024 and is expected to exhibit a CAGR of 5.4%
over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the global antibiotic resistance market are
Melinta Therapeutics, Merck & Co., Inc., Allergan, Pfizer Inc., Tetraphase
Pharmaceutical, Inc., Theravance Biopharma, WOCKHARDT, Entasis Threapeutics,
Paratek Pharmaceuticals, Inc., Seres Therapeutics, Achaogen Inc., Basilea
Pharmaceutical Ltd., Nabriva Threapeutics plc, and NEMESIS BIOSCIENCE LTD. The
increasing prevalence of antibiotic-resistant infections is fueling demand for
novel antimicrobial drugs and combination therapies. Major players are
investing in R&D to develop effective treatments targeting high priority
drug-resistant pathogens identified by WHO. Geographically, North America
dominates the market due to high healthcare spending and presence of key market
players. However, Asia Pacific is expected to witness fastest growth over the
forecast period with increasing healthcare investments.
Market Key Trends
Rising antibiotic resistance is a major public health concern globally. One
of the key trends in the
Global
Antibiotic Resistance Market Demand is increasing investment in
research for new treatment approaches such as alternatives to conventional
antibiotics like phages, antimicrobial peptides, and antivirulence compounds.
Other innovative pipelines include monoclonal antibodies, gene therapy, and
antipathogenic compounds that can neutralize pathogenic factors instead of
killing the pathogen. Companies are also developing rapid diagnostic kits than
can identify drug-resistant pathogens timely and aid clinicians in prescribing
optimal treatment regimens. Partnerships between public and private entities
are underway to strengthen the product pipeline and curb the growing resistance
problem worldwide.
Porter’s Analysis
Threat of new entrants: There is high regulatory and
capital costs that create significant entry barriers. Bargaining power of
buyers: Buyers have moderate bargaining power in terms of negotiating lower
prices and higher quality. However, prevalence of critical diseases maintains
some pricing power. Bargaining power of suppliers: Suppliers have moderate
bargaining power due to the importance of intellectual property and R&D
investments in developing new antibiotic formulations and technologies. There
is some threat to forward integration. Threat of new substitutes: There is a
growing threat from new substitute therapies such as vaccines and other
alternatives to conventional antibiotics. Competitive rivalry: Competition is
intense due to the number of major global players and potential for
differentiated yet similar offerings.
Geographical Regions
North America accounted for the largest share of the global antibiotic
resistance market value in 2024 due to the rising prevalence of chronic
diseases, growing elderly population, high healthcare spending, and presence of
major market players.
Asia Pacific is anticipated to be the fastest growing region during the
forecast period owing to increasing private and public healthcare investments,
large population base especially in India and China, growing awareness about
antibiotic resistance and prevalence of infectious diseases.
Get more insights on Global
Antibiotic Resistance Market
About Author:
Money Singh is a seasoned content writer with over
four years of experience in the market research sector. Her expertise spans
various industries, including food and beverages, biotechnology, chemical and
materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)
Comments
Post a Comment